APA (7th ed.) Citation

Weber, T., Mier, W., Sauter, M., Krämer, S., Jäger, D., Haberkorn, U., & Krauß, J. (2016). High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab. European journal of nuclear medicine and molecular imaging, 43(3), . https://doi.org/10.1007/s00259-015-3175-6

Chicago Style (17th ed.) Citation

Weber, Tobias, Walter Mier, Max Sauter, Susanne Krämer, Dirk Jäger, Uwe Haberkorn, and Jürgen Krauß. "High Treatment Efficacy by Dual Targeting of Burkitt’s Lymphoma Xenografted Mice with a 177Lu-based CD22-specific Radioimmunoconjugate and Rituximab." European Journal of Nuclear Medicine and Molecular Imaging 43, no. 3 (2016). https://doi.org/10.1007/s00259-015-3175-6.

MLA (9th ed.) Citation

Weber, Tobias, et al. "High Treatment Efficacy by Dual Targeting of Burkitt’s Lymphoma Xenografted Mice with a 177Lu-based CD22-specific Radioimmunoconjugate and Rituximab." European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 3, 2016, https://doi.org/10.1007/s00259-015-3175-6.